InvestorsHub Logo
Followers 4
Posts 929
Boards Moderated 0
Alias Born 08/15/2006

Re: grich1 post# 6169

Monday, 04/23/2018 11:00:02 AM

Monday, April 23, 2018 11:00:02 AM

Post# of 21530
"The decision was made at the recommendation of an independent data monitoring committee, which reviewed a futility analysis of a phase 3 trial, Prothena said. In addition, a phase 2b study didn't meet its primary or secondary endpoints. The decision "comes as an early negative surprise," said RBC Capital Markets analyst Kennen MacKay."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News